MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma

被引:9
作者
Du, Wei [1 ]
Chen, Dayu [1 ]
Wei, Ke [1 ]
Yu, Duo [1 ]
Gan, Zhiqiang [1 ]
Xu, Guozheng [1 ]
Yao, Guojie [1 ]
机构
[1] Gen Hosp Cent Theater Command, Dept Neurosurg, 627 Wuluo Rd, Wuhan 430070, Hubei, Peoples R China
关键词
glioblastoma; immune evasion; miR-10b-5p; PD-L1; TET2; TET2; GROWTH;
D O I
10.1620/tjem.2023.J028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glioblastoma (GBM) is a highly aggressive primary brain tumor that shows intratumoral heterogeneity at the cellular and molecular level. Activation of programmed death receptor 1 (PD-1) interaction with its ligand PD-L1 is a well-known mechanism requisite for immune evasion deployed by malignant tumors including GBM. Herein, we set out to dissect the mechanism explaining the regulation of PD-L1 gene expression in GBM. The clinical samples consisted of 37 GBM tissues and 18 normal brain tissues. GBM cell model was treated by microRNA (miRNA) inhibitor, DNA constructs, and siRNAs. Assays of CCK-8 and Transwell insert were employed to assess the survival, migratory and invasive ability of GBM cell model. The immunosuppressive factor production, T cell apoptosis, and T cell cytotoxicity to GBM cells were evaluated in the co-culture system. GBM exhibited more miR-10b-5p abundance than normal at both tissue and cellular level. Suppression of miR-10b-5p weakened the ability of GBM cell model to survive, migrate, and invade, decreased the release of immunosuppressive factors, reduced T cell apoptosis, and strengthened the T cell cytotoxicity to GBM cell model. MiR-10b-5p conferred a negative control of Ten-eleven translocation 2 (TET2) that was downregulated in GBM. The functions of miR-10b-5p on GBM cell aggressiveness and immune evasion were mediated by TET2. TET2 recruited histone deacetylases HDAC1 and HDAC2 into the PD-L1 promoter region thus inhibiting its transcription. The study demonstrated the importance of miR-10b-5p-mediated repression of TET2 in PD-L1-driven immune evasion and their potential for immunotherapeutic targeting in GBM.
引用
收藏
页码:205 / 214
页数:10
相关论文
共 36 条
[31]   Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: first steps toward the clinic [J].
Teplyuk, Nadiya M. ;
Uhlmann, Erik J. ;
Gabriely, Galina ;
Volfovsky, Natalia ;
Wang, Yang ;
Teng, Jian ;
Karmali, Priya ;
Marcusson, Eric ;
Peter, Merlene ;
Mohan, Athul ;
Kraytsberg, Yevgenya ;
Cialic, Ron ;
Chiocca, E. Antonio ;
Godlewski, Jakub ;
Tannous, Bakhos ;
Krichevsky, Anna M. .
EMBO MOLECULAR MEDICINE, 2016, 8 (03) :268-287
[32]   Glioblastoma: Current Status, Emerging Targets, and Recent Advances [J].
Thakur, Amandeep ;
Faujdar, Chetna ;
Sharma, Ram ;
Sharma, Sachin ;
Malik, Basant ;
Nepali, Kunal ;
Liou, Jing Ping .
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (13) :8596-8685
[33]   An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment [J].
Verdugo, Elena ;
Puerto, Iker ;
Angel Medina, Miguel .
CANCER COMMUNICATIONS, 2022, 42 (11) :1083-1111
[34]   Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy [J].
Xu, Yan-ping ;
Lv, Lei ;
Liu, Ying ;
Smith, Matthew D. ;
Li, Wen-Cai ;
Tan, Xian-ming ;
Cheng, Meng ;
Li, Zhijun ;
Bovino, Michael ;
Aube, Jeffrey ;
Xiong, Yue .
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (10) :4316-4331
[35]   TET3 Inhibits Type I IFN Production Independent of DNA Demethylation [J].
Xue, Shengjie ;
Liu, Chang ;
Sun, Xiujie ;
Li, Weiyun ;
Zhang, Chi ;
Zhou, Xin ;
Lu, Yao ;
Xiao, Jun ;
Li, Chunyang ;
Xu, Xiaoyan ;
Sun, Bing ;
Xu, Guoliang ;
Wang, Hongyan .
CELL REPORTS, 2016, 16 (04) :1096-1105
[36]   Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6 [J].
Zhang, Qian ;
Zhao, Kai ;
Shen, Qicong ;
Han, Yanmei ;
Gu, Yan ;
Li, Xia ;
Zhao, Dezhi ;
Liu, Yiqi ;
Wang, Chunmei ;
Zhang, Xiang ;
Su, Xiaoping ;
Liu, Juan ;
Ge, Wei ;
Levine, Ross L. ;
Li, Nan ;
Cao, Xuetao .
NATURE, 2015, 525 (7569) :389-+